Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01924364
Other study ID # PRO12030255
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 30, 2012
Est. completion date September 28, 2016

Study information

Verified date April 2018
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall purpose of this research is to evaluate the physical changes that occur over time after fat grafting for craniofacial trauma. This protocol is similar to an existing study (IRB# PRO0906101) presently conducted at the University of Pittsburgh by the same research team which utilizes fat grafts. The preparation of the fat graft material in each clinical trial is processed differently evaluating the effects of graft resorption after treatment.


Description:

The primary objective of the proposed clinical investigation of the Tissue Genesis Cell Isolation System™ (TGI CIS) device constitutes a feasibility study directed at an initial evaluation of the device in a certain clinical population, namely subjects undergoing craniofacial fat grafting.

1. Treat disfiguring craniofacial injuries in 5 subjects with fat grafting enhanced with adipose stromal vascular fraction (SVF) via TGI 1000 isolation methods to improve form with a high level of precision. Facial appearance and persistence of treatment effect will be assessed using aesthetic grading scales, state of the art 3-dimensional (3D) photography, and high resolution computed tomography (CT) scanning with 3D reconstruction. Patients will be followed for 24 months after treatment to define long term outcomes.

2. Assess biologic properties of the cells within the fat graft and correlate with clinical outcomes. This will include adipose stem cell yield per volume of fat tissue, cell proliferation, capacity for adipogenic differentiation, lipolysis, and cell sub-population analysis by multiparameter flow cytometry. Results of these assays will be correlated with graft volume retention to search for predictors of good clinical outcome that are related to variation on adipose biology between subjects.

3. Measure quality of life in patients before and after autologous fat grafting using validated psychosocial measures.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date September 28, 2016
Est. primary completion date September 28, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 1. Subjects who are male or female, military or civilian, 18 years of age or older and able to provide informed consent

2. Have suffered injury resulting in craniofacial volume defects which could be treated with a graft volume of between 3 and 100 cc of lipoaspirate

3. Be at least 3 months post-injury or post-surgery (from trauma procedures) so that acute edema is resolved

4. Volume defects are covered by intact skin and do not communicate with oral cavity or sinuses

5. The three dimensional geometry of the volume defects would allow for treatment with lipoaspirate injection so that at least two distinct treated areas could be discerned on gross examination and radiographically (e.g. treated regions are on opposite sides of the face, on lower face versus upper face, or separated by a bony landmark such as zygoma. This would include the ability to treat uninjured regions with fat grafts in order to obtain symmetry or balance.

6. Subjects who are, in the opinion of the Investigator, able to understand the study, comply with the study design and are willing to return to the clinic for all the research required follow-up visits

Exclusion Criteria:

- 1. Craniofacial defects intended for treatment have open wounds or communicate with oral cavity or sinus (note: presence of such a defect in the setting of another defect(s) that meets treatment criteria will not exclude the patient from participating).

2. Active infection anywhere in the body

3. Diagnosis of cancer within last 12 months and /or actively receiving chemotherapy or radiation treatment

4. Subjects with known idiopathic or drug-associated coagulopathy assessed by screening history and physical examination.

5. Subjects who have, as determined by the investigator a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study (i.e. Type 1 and Type 2 diabetic patients) or any condition within the last 14 days requiring hospitalization or surgical intervention.

6. Subjects who are pregnant, lactating, and women of child-bearing potential who are not abstinent or practicing an acceptable means of contraception, as determined by the Investigator, for the duration of the treatment phase

7. Subjects with known alcohol or narcotic drug dependency

8. Subjects with a history of abnormal blood biochemistry or any other abnormal laboratory findings, as defined by the normal value range within the UPMC Laboratory's value references and whose values are considered as determined by the investigator to be clinically significant, would render the subject inappropriate for the surgical procedures (i.e. CBC with Differential, platelets, comprehensive metabolic panel to include electrolytes, bun/creatinine, liver function test and coagulation tests). Reference to UPMC Laboratory normal value document (Attachment # 18)

9. Subjects with a life expectancy of <9 months, terminal conditions or factors making follow-up difficult (e.g. no fixed address, telephone etc)

10. Subjects with a known allergy to collagenase, an ingredient used by the TGI CIS to process the SVF product.

11. Subjects with an Axis II to diagnosis DSM-IV (e.g., Schizophrenia, Bipolar Disorder). Subjects who are found to be stable on medication and receive psychiatric clearance could be eligible for study participation per the Physician's discretion.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Tissue Genesis Cell Isolation System™ (TGI CIS)
In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
Procedure:
Standard of care fat grafting
In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.

Locations

Country Name City State
United States University of Pittsburgh Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
J. Peter Rubin, MD

Country where clinical trial is conducted

United States, 

References & Publications (2)

Yoshimura K, Sato K, Aoi N, Kurita M, Hirohi T, Harii K. Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. Aesthetic Plast Surg. 2008 Jan;32(1):48-55; discussion 56-7. Epub 2007 Sep 1. — View Citation

Zhu M, Zhou Z, Chen Y, Schreiber R, Ransom JT, Fraser JK, Hedrick MH, Pinkernell K, Kuo HC. Supplementation of fat grafts with adipose-derived regenerative cells improves long-term graft retention. Ann Plast Surg. 2010 Feb;64(2):222-8. doi: 10.1097/SAP.0b013e31819ae05c. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Total Fat Volume Injected and Facial Volume Postop Facial appearance and persistence of treatment effect will be assessed using high resolution CT scanning with 3D reconstruction. Patients will be followed for 24 months after treatment to define long term outcomes. Surgical visit, PO Study visits month 3, month 9, month 12, and month 24
Secondary Adipose Stem Cell Yield Per Volume of Fat Tissue this describes the biologic properties of the cells within the fat graft Surgical visit
See also
  Status Clinical Trial Phase
Completed NCT01345591 - A Study to Evaluate the Results of Facial Soft Tissue Reconstruction in Patients Who Have Suffered Traumatic Injury N/A
Completed NCT02267187 - Structural Fat Grafting for Craniofacial Trauma Using Manual Technique for Processing Fat Graft Material N/A
Completed NCT01054846 - Impact of Helmet Use in Preschool Children N/A
Not yet recruiting NCT05699187 - Face Transplantation N/A
Recruiting NCT02394990 - Violence Brief Intervention Pilot v1.1 N/A
Recruiting NCT02158793 - Craniomaxillofacial Allotransplantation N/A
Completed NCT00200135 - Financial and Clinical Impact of Repeal of the Pennsylvania Motorcycle Helmet Law N/A
Recruiting NCT04057638 - Craniomaxillofacial and Upper Extremity Allotransplantation N/A
Completed NCT03423277 - Easy Stretch Toolkit: A Pilot Study N/A
Recruiting NCT06163209 - Ultrasonography in the Diagnosis of Nasal Fractures
Recruiting NCT01889381 - Human Craniomaxillofacial Allotransplantation Phase 2
Completed NCT01822301 - Structural Fat Grafting for Craniofacial Trauma: Repeat Fat Grafting Injection-5 Subject Cohort N/A
Terminated NCT01564524 - Effect of Concentrating Endogenous Stromal Cells in the Fat Graft N/A